This press release contains forward-looking information on Pfizer`s efforts to combat COVID-19, cooperation between BioNTech and Pfizer for the development of a potential COVID 19 vaccine, the BNT162 vaccine programme, an agreement with the European Commission for the supply of BNT162 and other potential agreements, BNT162b2 and BNT162b2 (including qualitative assessments of available data, potential benefits, expectations for clinical trials, expected date of clinical studies and regulatory submissions, continued submission to the EMA, and expected production, distribution and delivery) that could result in significant risks and uncertainties that could lead to meaningful evidence. Risks and uncertainties include, among other things, uncertainties related to research and development, including the ability to meet expected clinical criteria, start and/or completion dates of clinical trials, delays in submitting legal approvals, approval dates and/or launch dates, as well as risks associated with preliminary and interim data (including Phase 3 intermediate data reviewed in this press release), including the possibility of adverse data for new clinical or clinical trials and other data analyses for preclinical or clinical clinical trials; the risk that data from clinical trials will be subject to different interpretations and evaluations, including during the peer review/publication process, in the scientific community in general and by regulators; whether and when data from the BNT162 mSA vaccine program will be published in specialized scientific journals and, if so, when and with what modifications; Whether regulators will be satisfied with the design and results of these preclinical and clinical and future trials; Whether and when applications for authorisation of biologics and/or emergency use authorization can be made in all legal systems of BNT162b2 or other potential vaccine candidates; whether and when such applications can be accepted by regulators, which will depend on countless factors, including determining the vaccine candidate`s benefits on known risks, and determining the effectiveness of the vaccine if approved, if approved, whether it will be concluded on the market; decisions made by regulators regarding labelling, manufacturing process, safety and/or any other issue that may affect the commercial availability or potential of a vaccine, including the development of products or therapies by other companies; disruptions in relations between us and our cooperation partners or third parties; Risks associated with the availability of raw materials for vaccine production; Challenges related to the formulation of our vaccine candidate`s ultra-low temperature and storage, distribution and management requirements, including the risks associated with handling after delivery by Pfizer; the risk that we will not be able to successfully develop unfrozen formulations; the risk that we will not be able to create or increase productive capacity in a timely manner or to have access to logistics or supply channels corresponding to global demand for a potential licensed vaccine, which would have a negative impact on our ability to provide the estimated number of doses of our vaccine candidate on time; If and when additional delivery agreements are reached Uncertainties about the ability to gather recommendations from technical immunization committees and other health authorities and uncertainties about the commercial impact of these recommendations; and the evolution of competition.

Comments are closed, but trackbacks and pingbacks are open.